-

12:32:13 AM

ZLAB Stock News

ZLAB - Zai Lab Limited

08/24/21 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentations in September Investor Conferences

Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in

RHEA-AI

neutral

08/09/21 4:30 PM

Nasdaq : ZLAB

earnings

Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced financial results for the second

RHEA-AI

positive

08/04/21 7:30 AM

Nasdaq : SDGR, ZLAB

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced a global discovery, development and

RHEA-AI

positive

08/04/21 7:30 AM

Nasdaq : ZLAB

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and

RHEA-AI

positive

07/22/21 7:30 AM

Nasdaq : ZLAB

earnings

Zai Lab to Announce Second Quarter 2021 Financial Results

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that it will report financial results and corporate updates for the second quarter ended June 30, 2021 after the

RHEA-AI

neutral

06/16/21 7:30 AM

Nasdaq : ZLAB

Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors Zai Lab provides rights to MacroGenics

RHEA-AI

very positive

06/01/21 7:30 AM

Nasdaq : ZLAB, MRTX

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the companies have

RHEA-AI

very positive

06/01/21 7:30 AM

Nasdaq : ZLAB

Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China

Zai Lab obtains the right to develop and exclusively commercialize adagrasib in mainland China, Hong Kong, Macau and Taiwan Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent tiered royalties

RHEA-AI

very positive

05/28/21 7:30 AM

Nasdaq : ZLAB

clinical trial

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first

RHEA-AI

very positive

05/25/21 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentations in June Investor Conferences

Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in

RHEA-AI

neutral

Prev 1 2 3 4 5 6 7 8 9 10 Next

ZLAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zailaboratory.com
Security nameZai Lab Limited - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressPudong
StateShanghai
CityShanghai
Zip201210
CountryChina (Mainland)

About Zai Lab Limited

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.